Analysis and Commentary STEVEN GROSSMAN 1/5/24 Analysis and Commentary STEVEN GROSSMAN 1/5/24 No Predetermined Outcome in Budget Negotiations Read More Advocacy at a Glance STEVEN GROSSMAN 12/15/23 Advocacy at a Glance STEVEN GROSSMAN 12/15/23 House Recesses with No Further Action on Appropriations; Senate to Resume Session Next Monday Read More Analysis and Commentary STEVEN GROSSMAN 12/15/23 Analysis and Commentary STEVEN GROSSMAN 12/15/23 Uncertainty, As Well As Risk to FDA in FY24 Appropriations Process Read More Advocacy at a Glance STEVEN GROSSMAN 12/8/23 Advocacy at a Glance STEVEN GROSSMAN 12/8/23 Negotiations on FY 2024 Appropriation Levels Continue Read More Analysis and Commentary STEVEN GROSSMAN 12/8/23 Analysis and Commentary STEVEN GROSSMAN 12/8/23 FDA Funding At Risk In Current Budget Negotiations Read More Advocacy at a Glance STEVEN GROSSMAN 12/1/23 Advocacy at a Glance STEVEN GROSSMAN 12/1/23 FDA Names Chief Scientist Bumpus as Dr. Woodcock’s Successor Read More Analysis and Commentary STEVEN GROSSMAN 12/1/23 Analysis and Commentary STEVEN GROSSMAN 12/1/23 What Must End, Will End. But When and How? Read More Advocacy at a Glance STEVEN GROSSMAN 11/17/23 Advocacy at a Glance STEVEN GROSSMAN 11/17/23 Laddered Continuing Resolution Signed by President Read More Analysis and Commentary STEVEN GROSSMAN 11/17/23 Analysis and Commentary STEVEN GROSSMAN 11/17/23 “Nothing Resolved. Everything Still on the Table.” Read More Analysis and Commentary STEVEN GROSSMAN 11/15/23 Analysis and Commentary STEVEN GROSSMAN 11/15/23 Shutdown Threats: Second Verse Same as the First; FDA Budget Still at Risk Read More Advocacy at a Glance STEVEN GROSSMAN 11/9/23 Advocacy at a Glance STEVEN GROSSMAN 11/9/23 Status of the Continuing Resolution Read More Advocacy at a Glance STEVEN GROSSMAN 11/3/23 Advocacy at a Glance STEVEN GROSSMAN 11/3/23 Senate Approves Agriculture/FDA Minibus Read More Analysis and Commentary STEVEN GROSSMAN 11/3/23 Analysis and Commentary STEVEN GROSSMAN 11/3/23 Level-Funding in FY 24: A Substantial Risk to FDA Priorities Read More Advocacy at a Glance STEVEN GROSSMAN 10/27/23 Advocacy at a Glance STEVEN GROSSMAN 10/27/23 Mike Johnson Elected as Speaker of the House - Further House Appropriations Action Proposed Read More Analysis and Commentary STEVEN GROSSMAN 10/27/23 Analysis and Commentary STEVEN GROSSMAN 10/27/23 Concrete Progress; Still A Long Way from Settling FDA’s FY 24 Funding Read More Advocacy at a Glance STEVEN GROSSMAN 10/23/23 Advocacy at a Glance STEVEN GROSSMAN 10/23/23 No Friday Update This Week - Quick Summary of the Ongoing Situation Read More Advocacy at a Glance STEVEN GROSSMAN 10/13/23 Advocacy at a Glance STEVEN GROSSMAN 10/13/23 Speaker Race in New Turmoil Read More Analysis and Commentary STEVEN GROSSMAN 10/13/23 Analysis and Commentary STEVEN GROSSMAN 10/13/23 FY 24 Appropriations: House Options Limited Regardless of Who Becomes Speaker Read More Advocacy at a Glance STEVEN GROSSMAN 10/6/23 Advocacy at a Glance STEVEN GROSSMAN 10/6/23 House Unlikely to Move Legislation Until New Speaker Selected Read More Analysis and Commentary STEVEN GROSSMAN 10/6/23 Analysis and Commentary STEVEN GROSSMAN 10/6/23 Lots to Learn from a Near-Shutdown Experience Read More Newer Posts Older Posts
Analysis and Commentary STEVEN GROSSMAN 1/5/24 Analysis and Commentary STEVEN GROSSMAN 1/5/24 No Predetermined Outcome in Budget Negotiations Read More
Advocacy at a Glance STEVEN GROSSMAN 12/15/23 Advocacy at a Glance STEVEN GROSSMAN 12/15/23 House Recesses with No Further Action on Appropriations; Senate to Resume Session Next Monday Read More
Analysis and Commentary STEVEN GROSSMAN 12/15/23 Analysis and Commentary STEVEN GROSSMAN 12/15/23 Uncertainty, As Well As Risk to FDA in FY24 Appropriations Process Read More
Advocacy at a Glance STEVEN GROSSMAN 12/8/23 Advocacy at a Glance STEVEN GROSSMAN 12/8/23 Negotiations on FY 2024 Appropriation Levels Continue Read More
Analysis and Commentary STEVEN GROSSMAN 12/8/23 Analysis and Commentary STEVEN GROSSMAN 12/8/23 FDA Funding At Risk In Current Budget Negotiations Read More
Advocacy at a Glance STEVEN GROSSMAN 12/1/23 Advocacy at a Glance STEVEN GROSSMAN 12/1/23 FDA Names Chief Scientist Bumpus as Dr. Woodcock’s Successor Read More
Analysis and Commentary STEVEN GROSSMAN 12/1/23 Analysis and Commentary STEVEN GROSSMAN 12/1/23 What Must End, Will End. But When and How? Read More
Advocacy at a Glance STEVEN GROSSMAN 11/17/23 Advocacy at a Glance STEVEN GROSSMAN 11/17/23 Laddered Continuing Resolution Signed by President Read More
Analysis and Commentary STEVEN GROSSMAN 11/17/23 Analysis and Commentary STEVEN GROSSMAN 11/17/23 “Nothing Resolved. Everything Still on the Table.” Read More
Analysis and Commentary STEVEN GROSSMAN 11/15/23 Analysis and Commentary STEVEN GROSSMAN 11/15/23 Shutdown Threats: Second Verse Same as the First; FDA Budget Still at Risk Read More
Advocacy at a Glance STEVEN GROSSMAN 11/9/23 Advocacy at a Glance STEVEN GROSSMAN 11/9/23 Status of the Continuing Resolution Read More
Advocacy at a Glance STEVEN GROSSMAN 11/3/23 Advocacy at a Glance STEVEN GROSSMAN 11/3/23 Senate Approves Agriculture/FDA Minibus Read More
Analysis and Commentary STEVEN GROSSMAN 11/3/23 Analysis and Commentary STEVEN GROSSMAN 11/3/23 Level-Funding in FY 24: A Substantial Risk to FDA Priorities Read More
Advocacy at a Glance STEVEN GROSSMAN 10/27/23 Advocacy at a Glance STEVEN GROSSMAN 10/27/23 Mike Johnson Elected as Speaker of the House - Further House Appropriations Action Proposed Read More
Analysis and Commentary STEVEN GROSSMAN 10/27/23 Analysis and Commentary STEVEN GROSSMAN 10/27/23 Concrete Progress; Still A Long Way from Settling FDA’s FY 24 Funding Read More
Advocacy at a Glance STEVEN GROSSMAN 10/23/23 Advocacy at a Glance STEVEN GROSSMAN 10/23/23 No Friday Update This Week - Quick Summary of the Ongoing Situation Read More
Advocacy at a Glance STEVEN GROSSMAN 10/13/23 Advocacy at a Glance STEVEN GROSSMAN 10/13/23 Speaker Race in New Turmoil Read More
Analysis and Commentary STEVEN GROSSMAN 10/13/23 Analysis and Commentary STEVEN GROSSMAN 10/13/23 FY 24 Appropriations: House Options Limited Regardless of Who Becomes Speaker Read More
Advocacy at a Glance STEVEN GROSSMAN 10/6/23 Advocacy at a Glance STEVEN GROSSMAN 10/6/23 House Unlikely to Move Legislation Until New Speaker Selected Read More
Analysis and Commentary STEVEN GROSSMAN 10/6/23 Analysis and Commentary STEVEN GROSSMAN 10/6/23 Lots to Learn from a Near-Shutdown Experience Read More
